Las Vegas—Findings from a new study of patients with spontaneous intracranial hemorrhage (ICrH) receiving a factor Xa (FXa) inhibitor found that andexanet alfa (Andexxa, Portola) halted bleeding in 79% of patients within 12 hours of administration.
“Ongoing bleeding is the most feared complication of ICrH, and so it is reassuring that most patients did not suffer this complication,” said lead investigator Joshua Goldstein, MD, PhD, a professor of emergency medicine